Home › Compare › MIUFY vs ABBV
MIUFY yields 3.01% · ABBV yields 3.06%● Live data
📍 MIUFY pulled ahead of the other in Year 7
Combined, MIUFY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MIUFY + ABBV for your $10,000?
Mitsubishi HC Capital Inc., together with its subsidiaries, engages in the lease, installment sale, and other financing activities in Japan, North America, Europe, the Middle and Near East, Asia/Oceania, and internationally. The company operates through Customer Business, Account Solution, Vendor Solution, LIFE, Real Estate, Environment & Renewable Energy, Aviation, Logistics, Mobility, and Others segments. It offers finance solutions for corporations, government agencies, and vendors; provides sales finance through collaboration with vendors; develops, operates, and leases logistics and commercial facilities; and engages in the community development, food, agriculture, living essentials industry, and non-life insurance businesses. The company also offers real estate securitization finance, as well as engages in the real estate investment, asset management, and leasing activities; and power generation through renewable energy, as well as provision of environment-related equipment leasing and financing services. In addition, it provides aircraft, aircraft engine, marine container, railway freight car, and auto leasing services; and medical equipment leasing and finance, and social infrastructure investment and finance services. Further, the company offers trust and settlement services. Mitsubishi HC Capital Inc. was incorporated in 1971 and is based in Tokyo, Japan.
Full MIUFY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.